DAPA-HF trial signals the birth of 'diabetic cardiology' and more

DAPA-HF trial signals the birth of 'diabetic cardiology' and more

[no abstract - showing first paragraph of article]Sodium-glucose co-transporter-2 (SGLT2) inhibitors are relatively new class of antihyperglycemic medication that is well established in the management of type 2 diabetes mellitus (DM). It has a unique mechanism of action that targets the kidneys thro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Global Cardiology Science & Practice 2020-11, Vol.2020 (2), p.e202022-e202022
Hauptverfasser: Wagdy, Kerolos, Selwanos, Peter
Format: Artikel
Sprache:eng
Schlagworte:
Lessons from the Trials
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[no abstract - showing first paragraph of article]Sodium-glucose co-transporter-2 (SGLT2) inhibitors are relatively new class of antihyperglycemic medication that is well established in the management of type 2 diabetes mellitus (DM). It has a unique mechanism of action that targets the kidneys through inhibiting 90% of glucose reabsorption.
ISSN:2305-7823
2305-7823
DOI:10.21542/GCSP.2020.22